Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis
T Kühbacher, S J Ott, U Helwig, T Mimura, F Rizzello, B Kleessen, P Gionchetti, M Blaut, M Campieri, U R Fölsch, M A Kamm, S Schreiber, T Kühbacher, S J Ott, U Helwig, T Mimura, F Rizzello, B Kleessen, P Gionchetti, M Blaut, M Campieri, U R Fölsch, M A Kamm, S Schreiber
Abstract
Background: The intestinal microbiota plays a critical role in the pathophysiology of pouchitis, a major complication after ileal pouch anal anastomosis in patients with ulcerative colitis. Recently, controlled trials have demonstrated that probiotics are effective in maintenance of remission in pouchitis patients. However, the mechanism by which therapy with probiotics works remains elusive. This study explores the role of the bacterial and fungal flora in a controlled trial for maintenance of remission in pouchitis patients with the probiotic VSL#3 compound.
Methods: The mucosa associated pouch microbiota was investigated before and after therapy with VSL#3 by analysis of endoscopic biopsies using ribosomal DNA/RNA based community fingerprint analysis, clone libraries, real time polymerase chain reaction (PCR), and fluorescence in situ hybridisation. Patients were recruited from a placebo controlled remission maintenance trial with VSL#3.
Results: Patients who developed pouchitis while treated with placebo had low bacterial and high fungal diversity. Bacterial diversity was increased and fungal diversity was reduced in patients in remission maintained with VSL#3 (p = 0.001). Real time PCR experiments demonstrated that VSL#3 increased the total number of bacterial cells (p = 0.002) and modified the spectrum of bacteria towards anaerobic species. Taxa specific clone libraries for Lactobacilli and Bifidobacteria showed that the richness and spectrum of these bacteria were altered under probiotic therapy.
Conclusions: Probiotic therapy with VSL#3 increases the total number of intestinal bacterial cells as well as the richness and diversity of the bacterial microbiota, especially the anaerobic flora. The diversity of the fungal flora is repressed. Restoration of the integrity of a "protective" intestinal mucosa related microbiota could therefore be a potential mechanism of probiotic bacteria in inflammatory barrier diseases of the lower gastrointestinal tract.
Conflict of interest statement
Conflict of interest: None declared.
Figures
References
- Madsen K L. The use of probiotics in gastrointestinal disease. Can J Gastroenterol 200115817–822.
- Montaldo M, Arancio F, Izzi al Probiotics: history, definition, requirements and possible therapeutic applications. Ann Ital Med Int 200217157–165.
- Shanahan F. Probiotics in inflamatory bowel disease. Gut 200148609
- Hart A L, Stagg A J, Frame al The role of the gut flora in health and disease, and its modification as therapy. Aliment Pharmacol Ther 2002161383–1393.
- Cremonimi E, Caro S, Santarelli al Probiotics in antibiotic associated diarrhoea. Dig Liver Dis 200234S78–S80.
- Isolauri E, Kirjavainen P V, Salminen S. Probiotic: a role in the treatment of intestinal infection and inflammation. Gut 20005054–59.
- Gionchetti P, Rizzello F, Venturi al Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double‐blind, placebo‐controlled trial. Gastroenterology 2000119305–309.
- Sen S, Mullan M M, Parker T al Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002472615–2620.
- Pochapin M. The effect of probiotics on Clostridium difficile diarrhoea. Am J Gastroenterol 200095S11–S13.
- Kruis W, Schutz E, Fric al Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 199711853–858.
- Furrie E, Macfarlane S, Kennedy al Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 200554242–249.
- Linskens R K, Huijsdens X W, Savelkoul P al The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl 200123429–40.
- Shibolet O, Karmeli F, Eliakim al Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 20028399–406.
- O'Mahony L, Freeney M, O'Halloran al Probiotic impact on microbial flora, inflammation and tumour development in IL‐10 knock‐out mice. Aliment Pharmacol Ther 2001151219–1225.
- Madsen K, Cornish A, Soper al Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001121580–591.
- Ulisse S, Gionchetti P, DÁlo al Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001962691–2699.
- Borruel N, Carol M, Casellas al Increased mucosal tumour necrosis factor {alpha} production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 200251659–664.
- Steidler L, Hans W, Schotte al Treatment of murine colitis by Lactococcus lactis secreting interleukin‐10. Science 20002891352–1355.
- Tannock G W, Munro K, Harmsen H al Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol 2000662578–2588.
- Bartosch S, Woodmansey E J, Paterson J al Microbiological effects of consuming a synbiotic containing Bifidobacterium bifidum, Bifidobacterium lactis, and oligofructose in elderly persons, determined by real‐time polymerase chain reaction and counting of viable bacteria. Clin Infect Dis 20054028–37.
- Simon G L, Gorbach S L. Intestinal flora in health and disease. Gastroenterology 198486174–193.
- Tannock G W. Molecular methods for exploring the intestinal ecosystem. Br J Nutr 200287S199–S201.
- Langendijk P, Schut F, Jansen al Quantitative fluorescence in situ hybridization of Bifidobacterium spp. with genus‐specific 16S rRNA‐targeted probes and its application in fecal samples. Appl Environ Microbiol 1995613069–3075.
- Wilson K, Blitchington R. Human colonic biota studied by ribosomal DNA sequence analysis. Appl Environ Microbiol 1996622273–2278.
- McFarlene G, Gibson G. Metabolic activities of the normal colonic microflora. In: Gibson S, ed. Human health: contribution of microorganisms. Frankfurt: Springer, Frankfurt, Germany, 199417–38.
- Zheng D, Alm E, Stahl al Characterization of universal small‐subunit rRNA hybridization probes for quantitative molecular microbial ecology studies. Appl Environ Microbiol 1996624504–4513.
- Zoetendal E G, Akkermans A D L, De Vos W M. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host‐specific communities of active bacteria. Appl Environ Microbiol 1998643854–3859.
- Swidsinski A, Ladhoff A, Pernthaler al Mucosal flora in inflammatory bowel disease. Gastroenterology 200212244–54.
- Zoetendal E G, von Wright A, Vilpponen‐Salmela al Mucosa‐associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 2002683401–3407.
- Seksik P, Rigottier‐Gois L, Gramet al Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 200352237–242.
- Walter J, Hertel C, Tannock G al Detection of Lactobacillus, Pediococcus, Leuconostoc, and Weissella species in human feces by using group‐specific PCR primers and denaturing gradient gel electrophoresis. Appl Environ Microbiol 2001672578–2585.
- Tannock G W. The bifidobacterial and Lactobacillus microflora of humans. Clin Rev Allergy Immunol 200222231–253.
- Dore J, Sghir A, Hannequart‐Gramet al Design and evaluation of a 16S rRNA‐targeted oligonucleotide probe for specific detection and quantitation of human faecal Bacteroides populations. Syst Appl Microbiol 19982165–71.
- Zoetendal E G, Ben‐Amor K, Harmsen H al Quantification of uncultured Ruminococcus obeum‐like bacteria in human fecal samples by fluorescent in situ hybridization and flow cytometry using 16S rRNA‐targeted probes. Appl Environ Microbiol 2002684225–4232.
- Kleessen B, Kroesen A J, Buhr H al Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol 2002371034–1041.
- Schwieger F, Tebbe C C. A new approach to utilize PCR‐single‐strand‐conformation polymorphism for 16S rRNA gene‐based microbial community analysis. Appl Environ Microbiol 1998644870–4876.
- Tebbe C C, Schmalenberger A, Peters al Single‐strand conformation polymorphism (SSCP) for microbial community analysis. In: Rochelle PA, ed. Environmental molecular microbiology: protocols and applications. Wymondham, UK: Horizon Scientific Press, 2001161–174.
- Valinsky L, Della Vedova G, Jiang al Oligonucleotide fingerprinting of rRNA genes for analysis of fungal community composition. Appl Environ Microbiol 2002685999–6004.
- Valinsky L, Della Vedova G, Scupham A al Analysis of bacterial community composition by oligonucleotide fingerprinting of rRNA genes. Appl Environ Microbiol 2002683243–3250.
- Stahlberg D, Gullberg K, Liljeqvist al Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum 1996391012–1018.
- Kock N G, Darle N, Hultén al Ileostomy. Curr Probl Surg 1977141–52.
- Parks A G, Nicholls R J. Proctocolectomy without ileostomy. BMJ 1978285–88.
- Sandborn W J. Pouchitis following ileal pouch‐anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 19941071856–1860.
- Svaninger G, Nordgren S, Oresland al Incidence and characteristics of pouchitis in the Kock continent ileostomy and the pelvic pouch. Scand J Gastroenterol 199328695–700.
- Hurst R D, Molinari M, Chung T al Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996131497–500.
- Madden M V, Farthing M J, Nicholls R J. Inflammation in the ileal reservoir: pouchitis. Gut 199031247–249.
- Meagher A P, Farouk R, Dozois R al J ileal pouch‐anal anastomosis for chronic ulcerative colitis: complication and long‐term outcome in 1310 patients. Br J Surg 199885800–803.
- Ruseler‐van Embden J G, Schouten W R, van Lieshout L M. Pouchitis: result of microbial imbalance? Gut 199435659–664.
- de‐Silva H J, Millard P R, Soper al Effects of the fecal stream and stasis on the ileal pouch mucosa. Gut 1991321166–1169.
- Madden M, McIntyre A, Nicholls R J. Double‐blind cross‐over trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 199439509–515.
- Mimura T, Rizzello F, Helwig al Randomised, placebo‐controlled, double‐blind trial of once daily, high dose probiotic therapy (VSL#3) for maintaining remission in patients with recurrent or refractory pouchitis. Gut 200453108–114.
- Gionchetti P, Rizzello F, Venturi al Antibiotic combination therapy in patients with chronic, treatment‐resistant pouchitis. Aliment Pharmacol Ther 199913713–718.
- Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology 19991161246–1260.
- Gionchetti P, Rizello F, Helwig al Prophylaxis of pouchitis onset with probiotic therapy: a double‐blind, placebo‐controlled trial. Gastroenterology 20031241202–1209.
- Sandborn W J, Tremaine W J, Batts K al Pouchitis after ileal pouch‐anal anastomosis: a pouchitis disease activity index. Mayo Clin Proc 199469409–415.
- Ott S J, Musfeldt M, Wenderoth D al Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 200453685–693.
- Ott S J, Musfeldt M, Ullmann al Quantification of intestinal bacterial populations by real‐time PCR with a universal primer set and minor groove binder probes: a global approach to the enteric flora. J Clin Microbiol 2004422566–2572.
- Lyons S R, Griffen A L, Leys E J. Quantitative real‐time PCR for porphyromonas gingivalis and total bacteria. J Clin Microbiol 2000382362–2365.
- Vainio E J, Hantula J. Direct analysis of wood‐inhabiting fungi using denaturing gradient gel electrophoresis of amplified ribosomal DNA. Mycol Res 2000104927–936.
- Newton C, Gomes M, Fagbola al Dynamics of fungal communities in bulk and Maize rhizosphere soil in the tropics. Appl Environ Microbiol 2003693758–3766.
- Thompson J R, Marcelino L A, Polz M F. Heteroduplexes in mixed‐template amplifications: formation, consequence and elimination by ‘reconditioning PCR'. Nucl Acids Res 2002302083–2088.
- Acinas S G, Klepac‐Ceraj V, Hunt D al Fine‐scale phylogenetic architecture of a complex bacterial community. Nature 2004430551–554.
- Manz W, Amann R, Ludwig al Application of a suite of 16S rRNA‐specific oligonucleotide probes designed to investigate bacteria of the phylum cytophaga‐flavobacter‐bacteroides in the natural environment. Microbiology 19961421097–1106.
- Franks A H, Harmsen H J M, Raangs G al Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group‐specific 16S rRNA‐targeted oligonucleotide probes. Appl Environ Microbiol 1998643336–3345.
- Harmsen H J, Raangs G C, He al Extensive set of 16S rRNA‐based probes for detection of bacteria in human feces. Appl Environ Microbiol 2002682982–2990.
- Luukkonen P, Jarvinen H, Tanskanen al Pouchitis‐recurrence of the inflammatory bowel disease? Gut 199435243–246.
- de Silva H J, Jones M, Prince al Lymphocyte and macrophage subpopulations in pelvic ileal pouches. Gut 1991321160–1165.
- Mahida J R, Patel S, Gionchetti al Macrophage subpopulations in the lamina propria of normal and inflamed colon and terminal leum. Gut 198930826–834.
- Onderdonk A B, Dvorak A M, Cisneros R al Microbiologic assessment of tissue biopsy samples from ileal pouch patients. J Clin Microbiol 199230312–317.
- Kmiot W A, Youngs D, Tudor al Mucosal morphology, cell proliferation, and fecal bacteriology in acute pouchitis. Br J Surg 1993801445–1449.
- Sandborn W J, McLeod R, Jewell D P. Medical therapy for induction and maintenance of remission in pouchitis: a systemic review. Inflamm Bowel Dis 1999533–39.
- Ott S J, Musfeldt M, Timmis K al In vitro alterations of intestinal bacterial microbiota in fecal samples during storage. Diagn Microbiol Infect Dis 200450237–245.
- Schumann A, Nutten S, Donnicola al Neonatal antibiotic treatment alters gastrointestinal tract developmental gene expression and intestinal barrier transcriptome. PhysiolGenomics200523235–245.
- Tamboli C P, Neut C, Desreumaux al Dysbiosis in inflammatory bowel disease. Gut 2004531–4.
- Rachmilewitz D, Katakura K, Karmeli al Toll‐like receptor 9 signaling mediates the anti‐inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004126520–528.
- Lionakis M S, Kontoyiannis D P. Glucocorticoids and invasive fungal infections. Lancet 20033621828–1838.
- Bernhard A E, Field K G. Identification of nonpoint sources of fecal pollution in coastal waters by using host‐specific 16S ribosomal DNA genetic markers from fecal anaerobes. Appl Environ Microbiol 2000661587–1594.
- von Wintzingerode F, Landt O, Ehrlich al Peptide nucleic acid‐mediated PCR clamping as a useful supplement in the determination of microbial diversity. Appl Environ Microbiol 200066549–557.
- Sghir A, Gramet G, Suau al Quantification of bacterial groups within human fecal flora by oligonucleotide probe hybridization. Appl Environ Microbiol 2000662263–2266.
- Guttman D S, Charlesworth D. An X‐linked gene with a degenerate Y‐linked homologue in a dioecious plant. Nature 1998393263–266.
Source: PubMed